Liquisolid Technology: Preparation, Characterization and Applications
With the advent of high throughput screening, drugs are emerging to be more lipophilic and less hydrophilic. Liquisolid Technology aims at solubility enhancement of such entities via cosolvency concept in a relatively minimalistic setup where there is no need of sophisticated machinery and is cost effective. It involves constituting a drug into molecular dispersion via a non-volatile solvent and then transforming it into a dry looking, free flowing compressible powder. This article aims at mapping Liquisolid Technology where its preparation techniques and potential applications are reviewed. An overview of the performance of Liquisolid in areas of dissolution enhancement, zero order release, photostability enhancement, liquipellets and its role in natural product formulations is recorded for a number of drugs.
Keywords: Liquisolid, Dissolution Enhancement, Flowability, Compressibility, Cosolvency
2. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced drug delivery reviews. 2012 Sep 13; 64:4-17
3. Ghadi R, Dand N. BCS class IV drugs: Highly notorious candidates for formulation development. Journal of Controlled Release. 2017 Feb 28; 248:71-95
4. Toutain PL, Bousquet‐Mélou A. Bioavailability and its assessment. Journal of veterinary pharmacology and therapeutics. 2004 Dec; 27(6):455-66
5. Spireas S. Liquisolid systems and methods of preparing same. US6423339B1; 2002
6. Spireas SS, Jarowski CI, Rohera BD. Powdered solution technology: principles and mechanism. Pharm Res 1992; 9:1351-8
7. Grover R, Spireas S, Lau-Cam C. Development of a simple spectrophotometric method for propylene glycol detection in tablets. J Pharm Biomed Anal 1998; 16:931-8
8. Spireas S, Sadu S. Enhancement of prednisolone dissolution properties using liquisolid compacts. Int J Pharm 1998;166:1771-88
9. Spireas S, Wang T, Grover R. Effect of powder substrate on the dissolution properties of methyclothiazide liquisolid compacts. Drug Dev Ind Pharm 1999; 25:163-8
10. Spireas S, Sadu S, Grover R. Invitro release evaluation of hydrocortisone liquisolid tablets. J Pharm Sci 1998; 87:867-72
11. Khaled KA, Asiri YA, El-SayedYM. In vivo evaluation of hydrochlorothiazide liquisolid tablets in beagle dogs.Int J Pharm 2001; 222:1-6
12. Javadzadeh Y, Jafari-Navimipour B, Nokhodchi A. Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine). Int J Pharm 2007; 341:26-34
13. Javadzadeh Y, Siahi MR, AsnaashariS,et al. An investigation of physicochemical properties of piroxicam liquisolid compacts. Pharm Dev Technol 2007; 12:337-43
14. Javadzadeh Y, Musaalrezaei L, Nokhodchi A. Liquisolid technique asa new approach to sustain propranolol hydrochloride release from tablet matrices. Int J Pharm2008; 362:102-8
15. Javadzadeh Y, Siahi MR, Asnaashari S, et al. Liquisolid technique as a tool for enhancement of poorly water-soluble drugs and evaluation oftheir physicochemical properties. Acta Pharm 2007; 57:99-109
16. Javadzadeh Y, Shariati H, Movahhed-Danesh E, et al. Effectof some commercial gradesofmicrocrystalline cellulose on flowability, compressibility, and dissolution profile of piroxicam liquisolid compacts. Drug Dev Ind Pharm 2009; 35:243-51
17. Nokhodchi A, Aliakbar R, Desai S, Javadzadeh Y. Liquisolid compacts: the effect of cosolvent and HPMC on theophylline release. ColloidsSurfB Biointerfaces 2010; 79:262-9
18. Fahmy RH, Kassem MA.Enhancement of famotidine dissolution rate through liquisolid tablets formulation: in vitro and in vivo evaluation. EurJPharm Biopharm 2008; 69:993-1003
19. Tayel SA, Soliman II, Louis D. Improvement of dissolution properties of Carbamazepinethrough application of the liquisolid tablet technique. EurJ Pharm Biopharm 2008; 69:342-347
20. Tiong N, Elkordy AA. Effects of liquisolid formulations on dissolutionof naproxen. Eur J Pharm Biopharm 2009; 73:373-84
21. Hentzschel CM, Sakmann A, Leopold CS. Suitability of various tableting excipients as carriersforliquisolid systems.Drug Development and Industrial Pharmacy. 2011; 37(10):1200–1207
22. Chella N, Shastri N, Tadikonda RR. Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan. Acta Pharmaceutica Sinica B. 2012 Oct 1; 2(5):502-8.
23. Elkordy AA, Essa EA, Dhuppad S, Jammigumpula P. Liquisolid technique to enhance and to sustain griseofulvin dissolution: Effect of choice of non-volatile liquid vehicles. International Journal of Pharmaceutics. 2012 Sep 15; 434(1-2):122-32.
24. Hentzschel CM, Alnaief M, Smirnova I, Sakmann A, Leopold CS. Enhancement of griseofulvin release from liquisolid compacts. European Journal of Pharmaceutics and Biopharmaceutics. 2012 Jan 1; 80(1):130-5.
25. Khanfar M, Sheikh Salem M, Hawari R. Formulation factors affecting the release of ezetimibe from different liquisolid compacts. Pharmaceutical development and technology. 2013 Apr 1; 18(2):417-27.
26. Chen B, Wang Z, Quan G, Peng X, Pan X, Wang R, Xu Y, Li G, Wu C. In vitro and in vivo evaluation of ordered mesoporous silica as a novel adsorbent in liquisolid formulation. International journal of nanomedicine. 2012; 7:199.
27. Singh SK, Srinivasan KK, Gowthamarajan K, Prakash D, Gaikwad NB, Singare DS. Influence of formulation parameters on dissolution rate enhancement of glyburide using liquisolid technique. Drug development and industrial pharmacy. 2012 Aug 1; 38(8):961-70.
28. Pavani E, Noman S, Syed IA. Liquisolid technique based sustained release tablet of trimetazidine dihydrochloride. Drug Invention Today. 2013 Dec 1; 5(4):302-10.
29. Elkordy AA, Tan XN, Essa EA. Spironolactone release from liquisolid formulations prepared with Capryol™ 90, Solutol® HS-15 and Kollicoat® SR 30 D as non-volatile liquid vehicles. European journal of pharmaceutics and biopharmaceutics. 2013 Feb 1; 83(2):203-23.
30. Khames A. Liquisolid technique: a promising alternative to conventional coating for improvement of drug photostability in solid dosage forms. Expert opinion on drug delivery. 2013 Oct 1; 10(10):1335-43.
31. Khanfar M, Sheikh Salem M, Kaddour F. Preparation of sustained-release dosage form of Venlafaxine HCl using liquisolid technique. Pharmaceutical development and technology. 2014 Feb 1; 19(1):103-15.
32. Sayyad FJ, Tulsankar SL, Kolap UB. Design and development of liquisolid compact of candesartan cilexetil to enhance dissolution. Journal of pharmacy research. 2013 May 1; 7(5):381-8.
33. Wang L, Feng R, Gao J, Xi Y, Huang G. Generic sustained release tablets of trimetazidine hydrochloride. Expert Opin Emerg Drugs. 2010; 15:283-98.
34. Badawy MA, Kamel AO, Sammour OA. Use of biorelevant media for assessment of a poorly soluble weakly basic drug in the form of liquisolid compacts: in vitro and in vivo study. Drug delivery. 2016 Mar 23; 23(3):808-17.
35. Mahajan HS, Patil SK, Nerkar PP. Liquisolid Compact of Gliclazide for Enhanced Dissolution and Oral Bioavailability. IJNDD Oct-Dec 2014; 6(4): 314-320.
36. Sanka K, Poienti S, Mohd AB, Diwan PV. Improved oral delivery of clonazepam through liquisolid powder compact formulations: in-vitro and ex-vivo characterization. Powder technology. 2014 Apr 1; 256:336-44.
37. Suliman AS, Anderson RJ, Elkordy AA. Norfloxacin as a model hydrophobic drug with unique release from liquisolid formulations prepared with PEG200 and Synperonic PE/L-61 non-volatile liquid vehicles. Powder technology. 2014 May 1; 257:156-67.
38. Suliman AS, Anderson RJ, Elkordy AA. Preparation of novel optimum liquisolid compacts via incorporating water granulation process to enhance the powder characterizations and dissolution behavior of a poorly soluble drug: Norfloxacin. Powder Technology. 2019 Sep 1;354:259-70.
39. Komala DR, Janga KY, Jukanti R, Bandari S, Vijayagopal M. Competence of raloxifene hydrochloride loaded liquisolid compacts for improved dissolution and intestinal permeation. Journal of Drug Delivery Science and Technology. 2015 Dec 1; 30:232-41.
40. Sharma V, Pathak K. Effect of hydrogen bond formation/replacement on solubility characteristics, gastric permeation and pharmacokinetics of curcumin by application of powder solution technology. Acta Pharmaceutica Sinica B. 2016 Nov 1; 6(6):600-13.
41. Lu M, Xing H, Yang T, Yu J, Yang Z, Sun Y, Ding P. Dissolution enhancement of tadalafil by liquisolid technique. Pharmaceutical development and technology. 2017 Jan 2; 22(1):77-89.
42. Pezzini BR, Beringhs AO, Ferraz HG, Silva MA, Stulzer HK, Sonaglio D. Liquisolid technology applied to pellets: Evaluation of the feasibility and dissolution performance using felodipine as a model drug. Chemical Engineering Research and Design. 2016 Jun 1; 110:62-9.
43. Vraníková B, Pavloková S, Gajdziok J. Experimental design for determination of effects of superdisintegrant combinations on liquisolid system properties. Journal of pharmaceutical sciences. 2017 Mar 1; 106(3):817-25.
44. Vraníková B, Gajdziok J, Doležel P. The effect of superdisintegrants on the properties and dissolution profiles of liquisolid tablets containing rosuvastatin. Pharmaceutical development and technology. 2017 Feb 17; 22(2):138-47.
45. Khames A. Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique. Drug delivery. 2017 Jan 1; 24(1):328-38.
46. Jadhav NR, Irny PV, Patil US. Solid state behavior of progesterone and its release from Neusilin US2 based liquisolid compacts. Journal of Drug Delivery Science and Technology. 2017 Apr 1; 38:97-106.
47. Baranauskaite J, Kopustinskiene DM, Masteikova R, Gajdziok J, Baranauskas A, Bernatoniene J. Effect of liquid vehicles on the enhancement of rosmarinic acid and carvacrol release from oregano extract liquisolid compacts. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2018 Feb 20; 539:280-90.
48. Jaipakdee N, Limpongsa E, Sripanidkulchai BO, Piyachaturawat P. Preparation of Curcuma comosa tablets using liquisolid techniques: in vitro and in vivo evaluation. International journal of pharmaceutics. 2018 Dec 20; 553(1-2):157-68.
49. Lu M, Xing H, Jiang J, Chen X, Yang T, Wang D, Ding P. Liquisolid technique and its applications in pharmaceutics. asian journal of pharmaceutical sciences. 2017 Mar 1; 12(2):115-23.
50. Nokhodchi A, Hentzschel CM, Leopold CS. Drug release from liquisolid systems: speed it up, slow it down. Expert opinion on drug delivery. 2011 Feb 1; 8(2):191-205.
51. Barua D, Indurkhya A, Maheshwari RK, Patel PK. Formulation of Rifabutin Liquisolid system using mixed solvency concept and their evaluation. International Journal of Research in Pharmacy and Pharmaceutical Sciences. 2019 Feb 11; 4(2): 7-12.
52. Anzilaggo D, Beringhs AO, Pezzini BR, Sonaglio D, Stulzer HK. Liquisolid systems: understanding the impact of drug state (solution or dispersion), nonvolatile solvent and coating material on simvastatin apparent aqueous solubility and flowability. Colloids and Surfaces B: Biointerfaces. 2019 Mar 1; 175:36-43.
53. Bonthagarala B, Dasari V, Kotra V, Swain S, Beg S. Quality-by-Design based development and characterization of pioglitazone loaded liquisolid compact tablets with improved biopharmaceutical attributes. Journal of Drug Delivery Science and Technology. 2019 Jun 1; 51:345-55.
54. Sharma V, Pathak K. Liquisolid system of paclitaxel using modified polysaccharides: In vitro cytotoxicity, apoptosis study, cell cycle analysis, in vitro mitochondrial membrane potential assessment, and pharmacokinetics. International journal of biological macromolecules. 2019 Sep 15; 137:20-31.
55. Mamidi HK, Mishra SM, Rohera BD. Determination of maximum flowable liquid-loading potential of Neusilin® US2 and investigation of compressibility and compactibility of its liquisolid blends with PEG (400). Journal of Drug Delivery Science and Technology. 2019 Dec 1; 54:101285.
56. Prajapat MD, Butani SB, Gohel MC. Liquisolid: A promising technique to improve dissolution efficiency and bioavailability of poorly water soluble nimodipine. Journal of Drug Delivery Science and Technology. 2019 Oct 1; 53:101135.
57. Zhang X, Xing H, Zhao Y, Ma Z. Pharmaceutical dispersion techniques for dissolution and bioavailability enhancement of poorly water-soluble drugs. Pharmaceutics. 2018 Sep; 10(3):74.
58. De Espíndola B, Beringhs AO, Sonaglio D, Stulzer HK, Silva MA, Ferraz HG, Pezzini BR. Liquisolid pellets: A pharmaceutical technology strategy to improve the dissolution rate of ritonavir. Saudi Pharmaceutical Journal. 2019 Jul 1; 27(5):702-12.
59. Lam M, Ghafourian T, Nokhodchi A. Optimising the release rate of naproxen liqui-pellet: a new technology for emerging novel oral dosage form. Drug Delivery and Translational Research. 2020 Feb 1; 10(1):43-58.
60. Lam M, Ghafourian T, Nokhodchi A. Liqui-pellet: the emerging next-generation oral dosage form which stems from liquisolid concept in combination with pelletization technology. AAPS PharmSciTech. 2019 Aug 1; 20(6):231.
61. Van Dooren AA. Design for drug-excipient interaction studies. Drug Development and Industrial Pharmacy. 1983 Jan 1; 9(1-2):43-55.
62. Carr RL, Carr RL, Carr RI, Carr R. Evaluating flow properties of solids. Chem. Eng. 1965; 72:163–168.
63. Saw HY, Davies CE, Paterson AH, Jones J. Correlation between powder flow properties measured by shear testing and Hausner ratio.
64. Powder Flow. The United States Pharmacopeia 30/National Formulary 25 (USP/NF). United States Pharmacopeial Convention, Rockville, MD, USA; 2007:1174
65. Walker EE. The properties of powders. Part VI. The compressibility of powders. Transactions of the Faraday Society. 1923; 19(July):73-82.
66. Nordström J, Welch K, Frenning G, Alderborn G. On the physical interpretation of the Kawakita and Adams parameters derived from confined compression of granular solids. Powder Technology. 2008 Mar 10; 182(3):424-35.
67. Sonnergaard JM. A critical evaluation of the Heckel equation. International journal of pharmaceutics. 1999 Dec 20; 193(1):63-71.
68. Duckworth W. Discussion of ryshkewitch paper by winston duckworth. J. Am. Ceram. Soc.. 1953; 36:68.
69. Leuenberger H. The compressibility and compactibility of powder systems. International Journal of Pharmaceutics. 1982 Sep 1; 12(1):41-55.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).